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Abstract
Transfusion-related acute lung injury (TRALI) is a leading cause of transfusion-associated mortality that can occur with any
type of transfusion and is thought to be primarily due to donor antibodies activating pulmonary neutrophils in recipients.
Recently, a large prospective case controlled clinical study of cardiac surgery patients demonstrated that despite
implementation of male donors, a high incidence of TRALI still occurred and suggested a need for additional interventions
in susceptible patient populations. To examine if intravenous immunoglobulin (IVIg) may be effective, a murine model of
antibody-mediated acute lung injury that approximates human TRALI was examined. When BALB/c mice were injected with
the anti-major histocompatibility complex class I antibody 34-1-2s, mild shock (reduced rectal temperature) and respiratory
distress (dyspnea) were observed and pre-treatment of the mice with 2 g/kg IVIg completely prevented these symptoms. To
determine IVIg’s usefulness to affect severe lung damage, SCID mice, previously shown to be hypersensitive to 34-1-2s were
used. SCID mice treated with 34-1-2s underwent severe shock, lung damage (increased wet/dry ratios) and 40% mortality
within 2 hours. Treatment with 2 g/kg IVIg 18 hours before 34-1-2s administration completely protected the mice from all
adverse events. Treatment with IVIg after symptoms began also reduced lung damage and mortality. While the prophylactic
IVIg administration did not affect 34-1-2s-induced pulmonary neutrophil accumulation, bone marrow-derived neutrophils
from the IVIg-treated mice displayed no spontaneous ROS production nor could they be stimulated in vitro with fMLP or 34-
1-2s. These results suggest that IVIg prevents murine antibody-mediated acute lung injury at the level of neutrophil ROS
production and thus, alleviating tissue damage.
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Introduction
Transfusion related acute lung injury (TRALI) is currently
ranked as one of the most serious complications of blood
transfusion today [1,2]. The majority of TRALI reactions are
associated with the presence of anti-HLA and anti-neutrophil
antibodies in the transfused products [3–6]. It is thought that these
leukocyte antibodies primarily stimulate the production of reactive
oxygen species (ROS) by pulmonary neutrophils that damages
pulmonary vessel endothelium [7–12]. Of interest, not all
leukocyte antibodies cause TRALI in recipients displaying the
cognate antigen [9,10] and some antibodies e.g. anti-human
neutrophil antigen (HNA)-3a and anti-human leukocyte antigen
(HLA)-A2 are associated with clinically more severe TRALI
reactions [5,11,12]. Although the incidence of TRALI is still a
matter of debate [13], a recent large prospective clinical study
showed that in transfused cardiac surgery patients undergoing a
cardiopulmonary bypass procedure, the incidence of TRALI was
as high as 2.4 percent of all surgeries [14]. Currently, there is no
effective therapy for patients with TRALI reactions except for
supportive care such as discontinuation of the transfusion and
oxygen therapy.
There have been several animal models of human TRALI
including, for example, ex-vivo lung models showing the
importance of human anti-neutrophil antibodies in causing lung
damage and in vivo models demonstrating how biological response
modifiers e.g. lipids and/or platelet-derived CD40L can induce
recipient lung damage [15–19]. An in vivo murine model of
antibody-mediated TRALI was developed in 2006 and has also
shown several similarities with human TRALI induction. Looney
et al [20] observed that when BALB/c mice were injected with a
monoclonal anti-mouse MHC class I antibody (34-1-2s), signifi-
cant increases in excess lung water, lung vascular permeability and
mortality were observed within 2 hours. These adverse reactions
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31357were found to be due 34-1-2 s’s ability to activate reactive oxygen
species (ROS) production by recipient neutrophils in an Fc
receptor (FcR)-dependent manner [21]. We subsequently demon-
strated that compared with BALB/c mice, mice with severe
combined immunodeficiency (SCID) were acutely hypersensitive
to 34-1-2 s effects indicating that recipient lymphocytes are
important in significantly reducing severe lung damage induced
by 34-1-2s [21]. The immunopathologic mechanisms that 34-1-2s
utilize have become more complex as Strait et al has recently
shown that the antibody induces pulmonary damage by activating
macrophages to generate ROS in a complement (C5a)-dependent
process [22]. The importance of this latter finding may be that this
antibody-mediated model of acute lung injury has at least two
immunopathologic events leading to TRALI. Taken together,
animal models have been instrumental in better defining the
pathophysiology of TRALI reactions.
Immunoglobulin preparations extracted from human blood
have been used since the early 1950’s to treat immunodeficiency
diseases [23,24]. Intravenous immunoglobulin (IVIg) therapy is
also effective in treating bacterial/viral infections and immune
regulatory disorders, particularly immunohematologic disorders
such as immune thrombocytopeni a( I T P )a sw e l la sa u t o i m m u n e
neutropenia [25–29]. While it’s clear beneficial effects in these
disorders are well known, its mechanism of action is still debated
and several theories have evolved to explain IVIg effects [30–
39]. To date, prophylactic IVIg administration for antibody-
mediated TRALI has not been considered and in fact, there are
at least 4 case reports that have demonstrated that IVIg
infusions may actually be associated with TRALI reactions [40–
43]. The mechanism(s) of how IVIg may mediate TRALI in
these reports is unknown, however, given IVIg’s extensive use in
many different immune disorders, these TRALI incidences are
quite rare and have not limited IVIg’s usage. Since SCID mice,
which lack B cell or T cells, were hypersensitive to the effects of
34-1-2s and IVIg has beneficial effects in antibody-mediated
disorders, we hypothesized that IVIg may be beneficial for
preventing TRALI reactions. We report here that in mice
prophylactically administered IVIg, 34-1-2s adverse events are
completely prevented and the acute lung injury at least,
appeared to be prevented by IVIg’s ability to restrict neutrophil
ROS production.
Results
IVIg prophylactic treatment prevented 34-1-2s-induced
hypothermia in SCID mice
Body temperatures were monitored as a measure of systemic
shock induced by the 34-1-2s infusions. Compared with control
naı ¨ve mice, when either BALB/c or SCID mice were administered
9 mg/kg or 2.3 mg/kg 34-1-2s respectively, rectal temperatures
began to decrease within 3 minutes post infusion and were
significantly reduced by 30 minutes post infusion (Figure 1).
Maximal reductions were observed by 90 min post infusion and
did not recover in SCID mice whereas BALB/c mouse
temperature began to recover within the 2 hour duration of the
experiment (Figure 1). In contrast, compared with HSA-treated
control mice, if mice were prophylactically treated with either 1 or
2 g/kg of IVIg 18 hours before 34-1-2s infusion, no significant
hypothermia was observed at any time (Figure 1). To determine if
IVIg could protect mice undergoing TRALI reactions, when the
rectal temperatures decreased by 1uC in 34-1-2s-treated mice, they
were then treated iv with 1 g/kg of IVIg. IVIg treatment of either
BALB/c or SCID mice did not rescue the 34-1-2s-induced
hypothermia (Figure 1).
IVIg reversed 34-1-2s-induced edema
Post-mortem measurement of Wet/Dry (W/D) lung weight
ratios were used to determine lung water content, an indicator of
pulmonary vascular barrier failure. Compared with untreated
naı ¨ve mice or mice treated with HSA, W/D lung weight ratios of
SCID mice infused with 2 mg/kg 34-1-2s significantly increased
by 2 hours post 34-1-2s-infusion (Figure 2). This was also true in
BALB/c mice given the higher dose (9 mg/kg) of 34-1-2s, except
that the magnitude of lung injury was considerably less compared
with SCID mice (Figure 2). In contrast, prophylactic IVIg
treatment with either 1 or 2 g/kg of IVIg 18 hrs prior to 34-1-
2s infusion completely prevented this form of lung injury in either
mouse strain (Figure 2). This protection was dependent on intact
IVIg as F(ab9)2 fragments prepared from the IVIg did not affect
the 34-1-2s-induced lung damage in SCID mice (Figure 2). Acute
Figure 1. IVIg prevents 34-1-2s-induced hypothermia in BALB/c
and SCID mice. Systemic shock was measured by rectal temperatures
in A) BALB/c mice or B) SCID mice. In both panels, mice were either not-
treated (#) or administered 34-1-2s (N, 9 mg/kg for BALB/c mice and
2 mg/kg for SCID mice iv) or treated prophylactically with 2 g/kg of IVIg
18 hours before 34-1-2s infusion (n). Some SCID mice in panel B were
also treated with 1 g/kg of IVIg 18 hours before 34-1-2s infusion (,),
1 g/kg of IVIg within 3 minutes after 34-1-2s infusion (%) or 2 g/kg HSA
( ). Rectal temperatures were monitored at the indicated times after
TRALI induction. There were at least 5 mice per group. The data is
expressed as mean 6SEM rectal temperatures. Significance was
determined by Student’s t test at each time point between 34-1-2s
infused mice (N) and IVIg treated (n) mice (w,p ,0.02; ww,p ,0.01;
www p,0.0001).
doi:10.1371/journal.pone.0031357.g001
Prevention of ALI with IVIg
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infusion also significantly reduced the W/D ratio in BALB/c
mice and tended to reduce the ratio in the SCID mice (Figure 2).
IVIg treatment prevented 34-1-2s-induced mortality
Compared with control non-treated mice or 34-1-2s-treated
BALB/c mice, when SCID mice were infused with 34-1-2s, forty
percent mortality was observed within 60 minutes post mAb
infusion (Figure 3). In contrast, compared with control HAS
infusions, prophylactic IVIg treatment with either the 1 or 2 g/kg
doses 18 hours before TRALI induction completely prevented 34-
1-2s-induced mortality (Figure 3). Similarly, acute treatment with
1 g/kg of IVIg within 3 minutes after 34-1-2s infusion also
reduced mortality in the SCID mice (Figure 3).
IVIg treatment does not prevent MIP-2 production nor
pulmonary neutrophil accumulation in TRALI
The levels of the neutrophil chemotactic (CXCL2) chemokine
MIP-2 (murine equivalent to human IL-8) in serum and
pulmonary neutrophils were enumerated in the mouse groups.
Despite IVIg’s prophylactic ability to prevent the 34-1-2s TRALI
symptoms above, the IVIg pre-treatment did not prevent either in
vivo 34-1-2s-induced MIP-2 production (Figure 4) nor did it
reduce neutrophil accumulation within the lungs (Figure 5) of
either BALB/c or SCID mice.
IVIg effects in TRALI are associated with inhibition of 34-
1-2s-induced neutrophil ROS pathway activation
To assess the effects of IVIg on 34-1-2s-induced neutrophil
ROS production, bone marrow derived neutrophils were purified
from the indicated mice, labeled with DHR-123 and analyzed by
flow cytometry. Neutrophils purified from 34-1-2s-treated mice
Figure 2. IVIg prevents 34-1-2s-induced lung damage in BALB/
c and SCID mice. Wet/Dry ratios in non-treated (2) naı ¨ve BALB/c mice
(column 1) and treated (+) BALB/c mice (columns 2,3) or SCID mice
(columns 4–10) administered the indicated treatments (below left).
TRALI was induced with an iv injection of 2 mg/kg 34-1-2s iv for SCID
mice and 9 mg/kg 34-1-2s for BALB/c mice. Some mice were treated
prophylactically 18 hours before TRALI induction with either 2 g/kg of
IVIg (IVIg (2) 218 h), 1 g/kg of IVIg (IVIg (1) 218 h) or a control infusion
with 2 g/kg human serum albumin (HSA 218 h) or 1 g/kg IVIg F(ab9)2
fragments (F(ab9)2 218 h). The other mice were treated within
3 minutes after TRALI induction with 1 g/kg of IVIg (IVIg (1) +3 m).
Two hours after TRALI induction, the mice were sacrificed and lung wet/
dry (W/D) ratios were measured. The data is expressed as the individual
mouse W/D ratios in each group and means6SEM are also shown.
Statistics were performed using a one way ANOVA and the w indicates
significance (p,0.001) between the indicated comparisons.
doi:10.1371/journal.pone.0031357.g002
Figure 3. IVIg prevents 34-1-2s-induced TRALI mortality in
SCID mice. Kaplan-Meier survival plots of SCID mice (N=10 for each
dose group). SCID mice were not treated (#) or administered 34-1-2s
(N, 2 mg/kg). Some mice were treated prophylactically 18 hours before
34-1-2s infusion with either a control infusion of 2 g/kg HSA ( )o r2g /
kg of IVIg (n) or 1 g/kg of IVIg (,). The other mice were treated within
3 minutes after TRALI induction with 1 g/kg of IVIg (%). The data is
expressed as percentage of mice surviving at the indicated times after
TRALI induction. No BALB/c mice treated with 9 mg/kg 34-1-2s died
during the experimental protocol. Significance was determined by a
Log ranked Mantel-Cox test between 34-1-2s infused mice (N) and
prophylactically IVIg treated (n, 2 g/kg) mice); p=0.0289 (the survival
curves are significantly different.
doi:10.1371/journal.pone.0031357.g003
Figure 4. IVIg does not prevent 34-1-2s-induced MIP-2
production in vivo. BALB/c (#) or SCID mice (%) were injected iv
with 2 mg/kg or 9 mg/kg 34-1-2s respectively or BALB/c (N) or SCID
mice (&) were first treated with 2 g/kg IVIg (218 h) before 34-1-2s
injection and MIP-2 levels were measured in the sera of the mice at the
indicated times by commercial ELISA. The data is expressed as mean
MIP-2 concentration (+SEM) from 5 mice in each group.
doi:10.1371/journal.pone.0031357.g004
Prevention of ALI with IVIg
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naı ¨ve mice (Figure 6). In contrast, if the mice were pre-treated with
2 g/kg IVIg 18 hours before 34-1-2s-TRALI induction, the
neutrophils maintained near basal levels of spontaneous ROS
production similar to naı ¨ve mice (Figure 6). Neutrophils isolated
from IVIg pretreated mice also displayed significantly decreased
ROS production in response to in vitro stimulation with 34-1-2s
(Figure 7). When the neutrophils from IVIg pretreated mice were
assessed for other intracellular pathways leading to ROS
activation, it was observed that the fMLP but not the PMA-
induced pathway was inhibited by IVIg (Figure 7).
IVIg treatment on acid-induced acute lung injury (ALI)
As IVIg was able to block some pathways of neutrophil
activation but not others, we examined its protective effect in a
non-antibody acid induced lung injury model. Prophylactic
treatment with 2 g/kg of IVIg ip 18 hours before the induction
of acid-induced ALI showed a slight trend towards an attenuated
injury response in that the decline in SaO2 subsequent to acid
instillation was largely blocked, yet no significant differences in
peak inspiratory pressures or mouse W/D lung weight ratios were
detectable between saline and IVIg pretreated mice (Figure 8).
Discussion
The 34-1-2s murine acute lung injury model has been shown to
be a good approximation of human TRALI in that recipient mice
exhibit increased pulmonary permeability, pulmonary pathology
and mortality which are mediated by activated pulmonary
neutrophils in an FcR-dependent manner [20]. There is also
evidence suggesting that 34-1-2s can activate the generation of
C5a which stimulates macrophage ROS production [22]. In our
hands, BALB/c mice have milder respiratory symptoms after 34-
1-2s infusion whereas SCID mice are extremely hypersensitive to
34-1-2s [21]. Thus BALB/c mice may represent the milder form
of TRALI termed transfusion associated dyspnea (TAD) whereas
SCID mice share more in common with the severe, fatal form of
TRALI. We report here that prophylactic IVIg administration
completely prevented TAD and the severe form of TRALI e.g.
hypothermia, lung damage and mortality. The TRALI protective
effect of IVIg was not due to reducing pulmonary neutrophil
accumulation but was associated with direct inhibition of 34-1-2s’s
ability to activate ROS production. These results suggest that IVIg
may have a beneficial effect in reversing and preventing severe
TRALI reactions.
Although there are now at least 4 case reports (Evidence level
III) that have shown that IVIg infusions may be associated with
TRALI reactions [40–43], we reasoned that given the enormous
amount of IVIg infused into many thousands of patients world-
wide, these IVIg-TRALI adverse events actually represent
extremely rare occurrences. Of interest, there are also several
clinical and experimental reports that have demonstrated an IVIg-
beneficial effect in other types of inflammatory lung injury. For
example, IVIg infusion reduces lung injury in patients with Adult-
onset Still’s disease, patients after cardiac surgery as well as a
variety of patient groups that have an infection-related lung injury
[44–48]. We hypothesized that since IVIg treatment has beneficial
effects in a wide variety of antibody-mediated and inflammatory
pathologies, it would reduce the adverse effects of antibody-
mediated TRALI.
Experimentally, prophylactic treatment of mice with 1 or 2 g/
kg of IVIg 18 hours before TRALI induction completely
prevented systemic shock, lung damage and mortality induced
by the 34-1-2s antibody (Figures 1,2,3). While this may not be
logistically feasible clinically, it demonstrates at least, that the anti-
inflammatory effects induced by IVIg may be sufficient to
completely prevent antibody-mediated TRALI effects. To deter-
mine if acute TRALI reactions could be modulated by IVIg, we
first administered 34-1-2s and upon detecting a 1uC rectal
temperature fall (within 3 minutes after 34-1-2s infusion), the
mice were infused iv with 1 g/kg of IVIg. We observed that while
TRALI reactions still occurred particularly related to reduced
rectal temperature, the severe TRALI reactions e.g. lung edema
and mortality were reduced. The apparent reduced protection of
the acute IVIg treatment may be due to the smaller dose of IVIg
that was given by the iv route because of volume restrictions.
Nonetheless, IVIg was able to acutely reduce the severe effects of
34-1-2s supporting the notion that IVIg could be used as a therapy
for transfusion recipients undergoing severe TRALI reactions.
Figure 5. IVIg does not prevent 34-1-2s-induced pulmonary
neutrophil accumulation in BALB/c or SCID mice. Percentage of
neutrophils in cytospin samples of lungs from A) BALB/c mice or B) SCID
mice. Mice were either non-treated (Naı ¨ve), 34-1-2s-treated (9 mg/kg
for BALB/c mice and 2 mg/kg for SCID mice) or 34-1-2s and 2 g/kg IVIg
treated. Neutrophils were enumerated on cytospin slides using ImageJ
software. The data are expressed as percent neutrophils in total
nucleated cells. The w indicates significance (p,0.05) between naı ¨ve
mice and the other groups of mice Determined by Student’s t test.
doi:10.1371/journal.pone.0031357.g005
Prevention of ALI with IVIg
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Fc-dependent as F(ab9)2 fragments prepared from the IVIg were
not effective in reversing the lung damage. These results suggest
that the mechanism of action of IVIg in reversing TRALI may
have similarities to the Fc-dependent beneficial effects of IVIg in
other antibody-mediated disorders such as immune thrombocyto-
penia (ITP). Many experimentally supported hypotheses of IVIg’s
mechanism of action in ITP have been proposed including, for
example, reticuloendothelial Fc receptor blockade [30], Fc gamma
inhibitory receptor (R) mediated inhibition of phagocytosis [31],
antiidiotypic regulation [32,33], cytokine alterations [34,35] and
IVIg-mediated dendritic cell suppression of inflammation [36].
More recently, elegant studies have demonstrated that IVIg may
also mediate its effects by modulation of pro-inflammatory
cytokines such as IL-17 and anti-inflammatory T regulatory cells
which may exert their immunosuppressive effects via inhibition of
dendritic cells [37–39]. It is possible that IVIg may utilize one or
more of these mechanisms to prevent antibody-mediated TRALI
reactions. We are currently studying this.
Approximately 4% of surgical patients undergoing a cardiopul-
monary bypass (CPB) procedure have acute lung injury episodes
and have an increased risk of death [49]
and the majority of these
patients are transfused [50]. Recently, a large prospective case
controlled clinical study of cardiac surgery patients showed a high
incidence (approximately 2.4%) of TRALI despite the implemen-
tation of male donor plasma [14]. It suggested a need for
additional interventions in the susceptible population as has also
been previously postulated [51,52]. It is plausible that these large
elective patient groups could benefit from prophylactic IVIg
therapy before the procedure.
IVIG’s effects were not simply due to neutralization of 34-1-29s
because binding of 34-1-2s to leukocytes as measured by flow
cytometry was not inhibited by titrations of IVIg in vitro (JWS,
unpublished, Feb, 2011) and in vivo, IVIg failed to reduce 34-1-2s-
induced serum MIP-2 levels (Fig. 4) which are dependent on the
antibody’s ability to bind to its cognate antigen MHC class I. How
IVIg mediates the reversal of TRALI is currently unknown but
there are clues that may shed light on its mechanism of action. For
Figure 6. IVIg prevents spontaneous ROS production in SCID mice. The effect of the indicated in vivo treatments on spontaneous ROS
production. SCID mice were either not treated (Naı ¨ve) or treated with 2 g/kg IVIg and/or 2 mg/kg 34-1-2s and their neutrophils were purified from
bone marrow and tested for their ability to produce ROS spontaneously in vitro. Results are expressed as mean channel fluorescence of DHR-123
fluorescence (6SEM) from 10 mice per group. The time line at the top demonstrates the protocol timing and the insert graph shows a typical
histogram analysis of spontaneous DHR-123 fluorescence in the 3 indicated mouse groups. The w indicates significance (p,0.05) between naı ¨ve
mice and the other groups of mice determined by Student’s t test.
doi:10.1371/journal.pone.0031357.g006
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adhesion to endothelial cells and neutrophil apoptosis in an Fc
dependent manner [53–55]. It is also possible that IVIg has the
ability to dampen neutrophil activation in the lung and rescues the
adverse pulmonary effects. We tested this and found that although
prophylactic IVIg treatment did not significantly affect the ability
of 34-1-2s to stimulate MIP-2 production (Fig. 4) nor cause
pulmonary neutrophil accumulation (Fig. 5), it was able to
significantly inhibit 34-1-2s’s ability to induce neutrophil ROS
production in vitro (Fig. 6). In contrast, IVIg was not effective in
affecting PMA-induced neutrophil ROS production. Although the
relationship between acute lung injury and protein kinase C
activation is complex and has not yet been completely defined
[56], these pathways of lung injury are fundamentally different
with IVIg only being effective in a particular pathway of
neutrophil activation. Collectively, these results suggest that IVIg
mediates its effects via an FcR-dependent anti-inflammatory effect
on neutrophils that limits ROS production rather than the
prevention of binding of 34-1-2s to it’s cognate antigen e.g. MIP-2
production or other necessary steps necessary for the chemoat-
traction and physical trapping of neutrophils in the lung.
The effects of IVIg appeared to be rather specific to TRALI
because IVIg had only modest protective effects on acid-induced
ALI (Figure 7). Indeed, IVIg largely prevented acid-induced
hypoxemia, yet it did not attenuate the increase in peak inspiratory
pressure indicating reduced lung compliance; this correlated with
no reduction in the W/D lung weight ratio. While the partially
beneficial effects of IVIg in non-transfusion related ALI deserve
further analysis in future studies, the present observations support
the notion that IVIg confers its beneficial actions via distinct anti-
inflammatory pathways specific to the pathophysiology of the
disease being treated. In particular, IVIg was effective in 34-1-2s-
induced neutrophil activation and TRALI.
In summary, we have demonstrated that in contrast to the few
reports showingthat IVIg may be associated withTRALI reactions,
prophylactic IVIg administration significantly and substantially
protects mice from antibody-mediated TRALI and does so at the
level of neutrophil activation. Thus, IVIg could be considered as a
potential therapeutic for patients predisposed to TRALI reactions.
Methods
Mice
Male BALB/c mice or CB.17 (H-2
d, CB17/Icr-Prkdc
scid/IcrCrl)
severe combined immunodeficient (SCID) mice, 6–12 weeks of
age, were obtained from Jackson Laboratories (Bar Harbor, ME)
or Charles River Laboratories (Montreal, PQ, Canada). All animal
studies were approved by the St. Michael’s Hospital Animal Care
Figure 7. IVIg prevents in vitro stimulated ROS production in SCID mice. The effect of in vivo IVIg treatment on neutrophil ROS production
stimulated in vitro. Mice were either not treated (White bars) or treated with 2 g/kg IVIg (Black bars) and their neutrophils were purified and tested for
their ability to produce ROS in vitro after stimulation with 34-1-2s, fMLP or PMA. Results are expressed as mean channel fluorescence of DHR-123
fluorescence (6SEM) from 5 mice per group. The horizontal line represents baseline ROS production in non-stimulated neutrophils from naı ¨ve SCID
mice. The time line at the top demonstrates the protocol timing. The w indicates significance (p,0.05) between non-treated and IVIg treated mice in
each stimulation and determined by student’s t test.
doi:10.1371/journal.pone.0031357.g007
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absence of endogenous murine IgG, SCID mice were tested for
serum IgG by a murine IgG ELISA (Cedarlane Laboratories,
Mississauga, ON) and any leaky mouse (.30 ug IgG/ml serum)
was excluded from study.
IVIg administration
GamunexH (10%, Telecris Biotherapeutics, Mississauga, ON)
was used as IVIg in all experiments. For prophylactic treatment,
mice received doses (1 or 2 g/kg) of IVIg intraperitoneally (ip)
18 hours before TRALI induction with 34-1-2s. These ip doses
were well tolerated in control mice. To attempt a more clinically
relevant treatment scenario, some mice were treated intravenously
(iv) with a 1 g/kg dose of IVIg after the first symptom of 34-1-2s-
induced TRALI was observed (a rectal temperature decrease of
1uC within approximately 3 minutes post 34-1-2s injection). The
1 g/kg dose chosen was the highest iv (approximately 200 uL)
dose tolerated by control mice without causing volume overload
symptoms (lung edema).
Control human serum albumin (HSA, 25% w/v, Baxter
Healthcare Corporation, Westlake Village, CA, USA) was diluted
to a final concentration of 10% (w/v) with sterile PBS (pH 7.4) and
administered ip at a dose of 2 g/kg. Although the albumin dose
has a greater oncotic load than does IVIg, it did not adversely
affect the mice.
34-1-2s and Antibody-mediated TRALI Induction
The hybridoma 34-1-2s (ATCC, Manassas, VA) produces a
monoclonal antibody (IgG2a, k) against H-2K
d and H-2D
d MHC
class I molecules [57]. It was grown in protein-free hybridoma
medium, PFHM II, (Invitrogen, Burlington, ON) in CELLine
flasks (BD Biosciences, Bedford, MA) at 37uC and 5% CO2.
For antibody-mediated TRALI induction, mice were weighed
and then challenged intravenously (iv) via tail vein injection with
34-1-2s; SCID mice were treated with 2 mg/kg 34-1-2s (approx-
imately 50 ug of antibody in a 100 ul infusion per mouse) and
BALB/c mice were treated with 9 mg/kg 34-1-2s (approximately
200 ug of antibody in a 100 ul infusion per mouse); these infusions
approximate the volume of a plasma transfusion in humans. The
indicated physiological measurements were then performed at the
indicated time points post 34-1-2s infusion.
Acid-induced Acute Lung Injury (ALI) Induction
To compare if IVIg affects a more direct form of acute lung
injury, acid induced lung injury was also performed. Briefly, SCID
micewereanesthetizedbyintraperitonealinjectionofmedetomidine
(0.5 mg/kg, Domitor; Dr E. Graeub AG), fentanyl (0.05 mg/kg;
Janssen Cilag), and midazolam (5 mg/kg, Dormicum; Roche) and
placed on a homeothermic blanket (Harvard Apparatus) in supine
position. Body temperature was maintained at 37uC with a feedback
coupled rectal thermoprobe. After tracheotomy, mice were
intubated with a polyethylene tube (Portex FineBore Polythene
Tubing, 0.58 mm ID/0.96 mm OD; Smiths Medical International)
and ventilated with room air at 100 breaths/minute (tidal volume of
10 mL/kg at a positive end-expiratory pressure of 1 cmH2O;
miniVent, Harvard Apparatus). Airway pressure was digitally
recorded (DASYlab 32; Datalog GmbH) and arterial oxygen
saturation (SaO2) was continuously monitored by pulse oximetry
(MouseOx; Starr Life Sciences). Following baseline recordings,
2 mL/kgofhydrochloricacid (pH 1.0) wasinstilledintothetrachea,
and arterial oxygen saturation and airway pressure were monitored
for 2 hours at which time mice were sacrificed and lung wet-to-dry
weight ratio was quantified as a measure of lung edema.
Body Temperature measurements
Rectal temperatures were measured as an indicator of systemic
shock at 30 minute intervals up to 120 minutes post 34-1-2s mAb
infusion using a RET-3, Rectal probe for mice (VWR Interna-
tional, Mississauga, ON) connected to a Traceable Digital
Figure 8. IVIg has a modest protective effect in acid-induced
lung injury. IVIg partially protects from arterial hypoxemia, but not
changes in lung mechanics and edema formation in acid-induced lung
injury. SCID mice were pretreated with either saline (White bars) or 2 g/
kg of IVIg (Black bars) 18 hours before acid induced lung injury was
induced by intratracheal instillation of HCl (2 mL/kg bw at pH 1.0) (A)
Arterial oxygen saturation (SaO2) levels and (B) peak inspiratory
pressure were determined at baseline and 2 hours after instillation of
HCl. Wet-to-dry lung weight ratios (C) were determined 2 h after HCl
instillation. Data are expressed as means6SEM from n=5 animals in
each group. The w indicates significance (p,0.05) between baseline
and the treatment groups determined by Student’s t test.
doi:10.1371/journal.pone.0031357.g008
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Clifton, NJ).
Wet/Dry Lung Weight Ratio
As a measure of pulmonary edema, wet-to-dry lung weight
ratios were determined as previously described [21]. At the
indicated time post 34-1-2s infusion, mice were anaesthetized
using Avertin ip (2% final in PBS) and the chest cavity was
exposed. The left lung was excised from each mouse, weighed (wet
weight) and then dried in an oven at 60uC for $48 hrs and then
re-weighed for dry weight. The wet-to-dry weight ratio was
calculated as: net wet weight/net dry weight.
MIP-2 Measurements
Blood was collected from the indicated mice and sera was
generated on ice and tested for the presence of the CXCL2
chemokine Macrophage Inflammatory Protein 2 (MIP-2) using an
ultra-sensitive commercial solid-phase ELISA kit (Mouse
CXCL2/MIP-2 Quantikine ELISA Kit, R&D Systems, Cedarlane
Laboratories, Burlington, ON, Cat# MM200). The MIP-2 assay
had a sensitivity of .1.5 pg/ml.
Pulmonary neutrophil accumulation
Pulmonary neutrophils were enumerated as previously de-
scribed [21]. Briefly, each mouse was anaesthetized using Avertin
ip (2% final in PBS) and the chest cavity was exposed and the right
lung was isolated and excised. The lung was homogenized and the
cell suspension produced was filtered through a 40 mm cell strainer
(BD Biosciences, Bedford, MA). The cell suspension was then
washed and red blood cells were removed by Ammonium
Chloride/Potassium (ACK) lysis solution (0.15 M NH4Cl,
10 mM KHCO3,N a 2EDTA, pH 7.2–7.4). The cell preparation
was then washed twice with cold PBS and cells were mounted on
microscope slides using a Shandon Cytospin 4 (ThermoFisher
Scientific, Nepean, ON) and stained with a haematoxylin-and-
eosin (H&E) kit (Harleco - Hemacolor, EMD Chemicals, Inc.,
Darmstadt, Germany). The slides were then examined by light
microscopy using a microscope (Olympus Canada, Markham,
ON) with a 606 oil immersion lens. PMN were enumerated by
counting total nucleated cells in at least 3 equivalent fields and
neutrophils were enumerated by marking with ImageJ software.
Neutrophil enumeration was calculated as percent neutrophils of
total nucleated cells by the formula: Neutrophil counts/Total
nucleated cell counts 6100.
Neutrophil purification and in vitro activation studies
Neutrophils from the different mouse groups were collected
from the bone marrow and purified. Pulmonary neutrophils in 34-
1-2s-treated mice are very difficult to separate from the inflamed
lung tissue and were not used. Briefly, mice were sacrificed and
their femurs were removed, cleaned of tissue, epiphysises removed
and bone marrow was flushed out with a 25 g needle using an ice
cold 0.1% FCS/PBS solution. The cells were filtered through a
40 um cell strainer, counted and neutrophils were purified using a
mouse neutrophil enrichment kit (Stem Cell Technologies,
Vancouver, CA) and a magnetic activated cell sorter as described
in the manufacturers instructions. Purity of the neutrophils was
.96%. For in vitro activation, 2610
5 purified neutrophils in
100 ul of PBS were incubated in 1 uM of the ROS-specific
fluorochrome Dihydrorhodamine 123 (DHR-123) for 10 minutes
at 37uC. The labeled neutrophils were then incubated with either
nothing (spontaneous ROS), 2 ug/ml phorbol 12-myristate 13-
acetate (PMA) or 100 nM formyl-methionyl-leucyl-phenylalanine
(fMLP) or serial dilutions of 34-1-2s for 10 minutes at 37uC. The
cells were then incubated with 200 ul of DNA staining solution
(LDS751) on ice for 10 minutes in dark and acquired on a
FACSort flow cytometer (BD, Missisauga, ON) gated on LDS751
staining. DHR-123 fluorescence was analyzed as a measure of
ROS production.
Statistical Analysis
Significance between mouse groups was determined by various
statistical methods as indicated in each figure legend.
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